Qingdao Saber Technology Pharma QST
Tirzepatide
Finnrick tested 2 samples of Tirzepatide (GLP-1 and GIP antagonist) from Qingdao Saber Technology Pharma QST between 2 Jul 2025 and 25 Jul 2025. Test scores average below 4 or some scores below 3, and at least 2 tests, warrant a tentative Finnrick Rating of E (Bad).
Finnrick Rating™
Tentative Rating
Qingdao Saber Technology Pharma QST
Tirzepatide
Tested 2 Samples
Last test 25 Jul 2025
Take Action
Researcher
Request Full Data Access to the Finnrick database of peptide tests.
Free peptide testing
Mail in a sample (US only) to get confidence for the specific vials you have, and contribute to identifying unsafe supply chains, so other people can avoid risky and costly mistakes.
Other Tirzepatide tests from top-rated vendors:
All Tirzepatide tests from Qingdao Saber Technology Pharma QST
Samples are tested in commercial labs
Tests Count
2
Scores
AVGMINMAX
Last
25 Jul 2025
First
2 Jul 2025
| Quantity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Certificate | Test Score | Label | Tested | Difference | Purity | Batch ID | Container | Tested At | Sent By |
| 25 Jul 2025 | View | 30mg | 29.700mg | -1.0% | 99.82% | (no batch ID) | No Label / Silver Crimp / Red Cap | Lab E | Public | |
| 2 Jul 2025 | View | 15mg | ⚠️ Sample does not contain Tirzepatide | (no batch ID) | No Label / Silver Crimp / Red Cap | Lab E | Public | |||